These data are the first to demonstrate B7-H3 expression in osteosarcoma lesions and, more remarkably, suggest that B7-H3 may be clinically relevant in osteosarcoma, potentially facilitating tumor progression by undermining host immunity. This evidence concerns the gene CD276 and osteosarcoma.